The adjustment in price target by a reputable analyst firm like Cantor Fitzgerald, while maintaining an Overweight rating, suggests a positive outlook on AVITA Medical's fundamentals but with a slightly moderated growth expectation. This could lead to a neutral short-term impact on the stock as the market digests the slight reduction in the price target against the backdrop of continued analyst confidence.